BrainStorm Announces Grant of an additional New European Patent for NurOwn®
March 26 2019 - 6:30AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading
developer of adult stem cell therapeutics for neurodegenerative
diseases, today announced that the European Patent Office ("EPO")
has granted a European-wide patent titled 'Mesenchymal Stem Cells
for the treatment of CNS Diseases.' The European Patent Application
will be published in the European Patent Bulletin 19/13 on 27 March
2019, under Patent No. 2620493.
The allowed claims cover the isolated cells as
well as their use in the manufacture of a medicament for treating a
CNS disease or disorder, selected from the group consisting of:
Parkinson's, multiple sclerosis, epilepsy, amyotrophic
lateral sclerosis, stroke, autoimmune encephalomyelitis, diabetic
neuropathy, glaucomatous neuropathy, Alzheimer's disease and
Huntingdon's disease.
“We continue to protect our technology through strategic
intellectual property achievements and this Grant from the European
Patent Office is another welcome addition to our IP portfolio,”
commented BrainStorm's CEO, Chaim Lebovits. He added,
“Having a EU patented product should increase our ability to enter
into new commercial partnerships for NurOwn® in Europe”.
BrainStorm’s senior management team is
currently in Europe attending the 13th Annual
International Partnering Conference, BIO EUROPE
SPRING® (#BIOEuropeSpring), Vienna, March
25-28, where we are also exploring potential
partnering opportunities.”
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a
leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® technology platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement. Autologous MSC-NTF cells have received Orphan
Drug status designation from the U.S. Food and Drug
Administration (U.S. FDA) and the European Medicines
Agency (EMA) in ALS. BrainStorm is currently enrolling a Phase
3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute
for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study
is intended to support a filing for U.S. FDA approval of
autologous MSC-NTF cells in ALS. BrainStorm also recently received
U.S. FDA clearance to initiate a Phase 2 open-label
multicenter trial in progressive Multiple Sclerosis. The Phase 2
study of autologous MSC-NTF cells in patients with progressive MS
(NCT03799718) started enrollment in March 2019. For more
information, visit the company's website at
www.brainstormcell.com.
Safe-Harbor
Statement
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
Contacts
Corporate: Uri Yablonka Chief Business Officer
BrainStorm Cell Therapeutics Inc. Phone: 646-666-3188
uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR PR Phone:
+1.646.677.1839 sean.leous@icrinc.com
Investors: Michael Levitan Solebury Trout
Phone:+1.646.378.2920 mlevitan@soleburytrout.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Sep 2023 to Sep 2024